Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06909565 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Study acronym: V-INTERVENTION
StatusRecruiting
PhasePhase 4
Started2025-07-23
View on ClinicalTrials.gov ↗

Amendment history

2026-08-26
Study Status, Contacts/Locations v25
Trial sites expanded: 133 → 136 locations
2026-08-14
Study Status, Contacts/Locations v24
Trial sites expanded: 125 → 132 locations
2026-08-13
Study Status, Contacts/Locations v23
Study sites125→132
2026-08-03
Study Status, Contacts/Locations v22
Trial sites expanded: 115 → 125 locations
2026-07-22
Study Status, Contacts/Locations v21
Trial sites expanded: 112 → 115 locations
Show 3 earlier versions
2026-07-14
Study Status, Contacts/Locations v20
Study sites111→112
2026-07-10
Study Status, Contacts/Locations v19
Study sites110→111
2026-07-07
Study Status, Contacts/Locations v18
Study sites109→110
2026-07-01
Study Status, Contacts/Locations v17
Trial sites expanded: 103 → 107 locations
2026-06-29
Study Status, Contacts/Locations v16
Study sites103→107
2026-06-15
Study Status, Contacts/Locations v15
Study sites102→103
2026-06-08
Study Status, Contacts/Locations v14
Trial sites expanded: 99 → 102 locations
2026-06-03
Study Status, Contacts/Locations v13
Study sites100→99
2026-05-29
Study Status, Contacts/Locations v12
Trial sites expanded: 96 → 100 locations
2026-05-08
Study Status, Contacts/Locations v11
Trial sites expanded: 78 → 96 locations
2026-04-01
Study Status, Contacts/Locations v10
Trial sites expanded: 71 → 78 locations
2026-03-20
Study Status, Contacts/Locations v9
Study sites68→71
2026-03-11
Study Status, Contacts/Locations v8
Study sites53→68
2026-01-23
Study Status, Contacts/Locations v7
Study sites50→53
2026-01-14
Study Status, Contacts/Locations v6
Study sites44→50
2025-12-23
Study Status, Contacts/Locations v5
Study sites28→44
2025-12-09
Study Status, Contacts/Locations v4
Study sites16→28
2025-12-04
Study Status, Contacts/Locations v3
Study sites5→16
2025-08-01
Study Status, Contacts/Locations v2
Start dateestimated 2025-07→confirmed 2025-07-23
Study sites3→5
2025-07-23
Not Yet Recruiting→Recruiting Study Status, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2029-04→2029-10
Completion date2029-06→2029-12
Study sites0→3
2025-03-27
Original filing
Duke University
455 trials monitored
See 53 trials at risk
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
Trial Details
NCT Number NCT06909565
Lead Sponsor Duke University
Collaborators: Novartis Pharmaceuticals, Colorado Prevention Center, Mount Sinai Hospital, New York
Conditions Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Enrollment 6,000 participants
Start Date 2025-07-23
Primary Completion 2029-10 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-28